It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COR’s FA Score shows that 4 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COR’s TA Score shows that 3 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s).
COR (@Medical Distributors) experienced а +2.18% price change this week, while MRK (@Pharmaceuticals: Major) price change was +0.53% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +2.99%. For the same industry, the average monthly price growth was +0.75%, and the average quarterly price growth was -9.48%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.43%. For the same industry, the average monthly price growth was +3.13%, and the average quarterly price growth was -5.44%.
COR is expected to report earnings on Jul 30, 2025.
MRK is expected to report earnings on Jul 29, 2025.
Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
@Pharmaceuticals: Major (+2.43% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
COR | MRK | COR / MRK | |
Capitalization | 48.4B | 332B | 15% |
EBITDA | 3.71B | 6.91B | 54% |
Gain YTD | 30.309 | -15.663 | -194% |
P/E Ratio | 26.47 | 935.64 | 3% |
Revenue | 272B | 60.1B | 453% |
Total Cash | 2.87B | 7.09B | 40% |
Total Debt | 4.78B | 35.1B | 14% |
COR | MRK | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 1 | 69 | |
SMR RATING 1..100 | 10 | 24 | |
PRICE GROWTH RATING 1..100 | 26 | 63 | |
P/E GROWTH RATING 1..100 | 12 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (11) in the Pharmaceuticals Major industry is significantly better than the same rating for COR (96) in the Real Estate Investment Trusts industry. This means that MRK’s stock grew significantly faster than COR’s over the last 12 months.
COR's Profit vs Risk Rating (1) in the Real Estate Investment Trusts industry is significantly better than the same rating for MRK (69) in the Pharmaceuticals Major industry. This means that COR’s stock grew significantly faster than MRK’s over the last 12 months.
COR's SMR Rating (10) in the Real Estate Investment Trusts industry is in the same range as MRK (24) in the Pharmaceuticals Major industry. This means that COR’s stock grew similarly to MRK’s over the last 12 months.
COR's Price Growth Rating (26) in the Real Estate Investment Trusts industry is somewhat better than the same rating for MRK (63) in the Pharmaceuticals Major industry. This means that COR’s stock grew somewhat faster than MRK’s over the last 12 months.
COR's P/E Growth Rating (12) in the Real Estate Investment Trusts industry is significantly better than the same rating for MRK (100) in the Pharmaceuticals Major industry. This means that COR’s stock grew significantly faster than MRK’s over the last 12 months.
COR | MRK | |
---|---|---|
RSI ODDS (%) | 2 days ago45% | 2 days ago52% |
Stochastic ODDS (%) | 2 days ago52% | 2 days ago56% |
Momentum ODDS (%) | 2 days ago72% | 2 days ago51% |
MACD ODDS (%) | 2 days ago48% | 2 days ago50% |
TrendWeek ODDS (%) | 2 days ago61% | 2 days ago50% |
TrendMonth ODDS (%) | 2 days ago62% | 2 days ago43% |
Advances ODDS (%) | 3 days ago62% | 3 days ago48% |
Declines ODDS (%) | 9 days ago42% | 17 days ago48% |
BollingerBands ODDS (%) | 2 days ago51% | 2 days ago54% |
Aroon ODDS (%) | 2 days ago58% | 2 days ago41% |
A.I.dvisor indicates that over the last year, COR has been loosely correlated with MCK. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if COR jumps, then MCK could also see price increases.
Ticker / NAME | Correlation To COR | 1D Price Change % | ||
---|---|---|---|---|
COR | 100% | +0.58% | ||
MCK - COR | 63% Loosely correlated | +0.23% | ||
CAH - COR | 48% Loosely correlated | +2.75% | ||
OMI - COR | 20% Poorly correlated | +7.75% | ||
SHTDF - COR | 17% Poorly correlated | N/A | ||
EDAP - COR | 14% Poorly correlated | +3.25% | ||
More |
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with PFE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then PFE could also see price increases.
Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
---|---|---|---|---|
MRK | 100% | -0.10% | ||
PFE - MRK | 37% Loosely correlated | +1.13% | ||
AZN - MRK | 35% Loosely correlated | +2.74% | ||
BIIB - MRK | 34% Loosely correlated | +2.15% | ||
ABBV - MRK | 33% Loosely correlated | +2.65% | ||
NVS - MRK | 33% Loosely correlated | +2.66% | ||
More |